# Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer

> **NCT04085991** · PHASE2 · TERMINATED · sponsor: **Sir Mortimer B. Davis - Jewish General Hospital** · enrollment: 11 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Adenocarcinoma
- Prostatic Neoplasms
- Metastatic Prostate Cancer
- Metastatic Prostatic Adenocarcinoma
- Metastatic Prostate Carcinoma in the Soft Tissue

## Interventions

- **DRUG:** 131I-PSMA-1095 Radioligand Therapy (RLT)

## Key facts

- **NCT ID:** NCT04085991
- **Lead sponsor:** Sir Mortimer B. Davis - Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-31
- **Primary completion:** 2023-01-15
- **Final completion:** 2023-01-15
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Drug no longer available
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04085991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04085991, "Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04085991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*